NCT00839254 - Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A | Biotech Hunter

Enrollment

6,181

Participants

Timeline

Start Date

February 18, 2009

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Infections, StreptococcalStreptococcus Pneumoniae

Interventions

BIOLOGICAL

Pneumococcal conjugate vaccine Synflorix (GSK1024850A)

2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination

BIOLOGICAL

GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)

3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children \< 12 months of age at the time of first study vaccination.

BIOLOGICAL

GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)

2 Intramuscular injections only for children \>= 12 months of age at the time of first study vaccination.

Trial Locations (15)

15140

GSK Investigational Site, Lahti

20520

GSK Investigational Site, Turku

28100

GSK Investigational Site, Pori

33100

GSK Investigational Site, Tampere

48600

GSK Investigational Site, Kotka

60100

GSK Investigational Site, Seinäjoki

67100

GSK Investigational Site, Kokkola

70210

GSK Investigational Site, Kuopio

90220

GSK Investigational Site, Oulu

02100

GSK Investigational Site, Espoo

00100

GSK Investigational Site, Helsinki

00930

GSK Investigational Site, Helsinki

04400

GSK Investigational Site, Järvenpää

01300

GSK Investigational Site, Vantaa

01600

GSK Investigational Site, Vantaa